AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21714878 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day ribavirin (group D) for 16 weeks with high viral load
Number of subjects: 89
Study 21715313 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin
Number of subjects: 83
Study 21715509 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 g yellow maize porridge containing 1.2 mg β-carotene, 20 g butter, and a 0.5-g corn oil capsule
Number of subjects: 8
Study 21715509 — intervention group
Group type: COMPARATOR
Intervention: 1 mg [(13)C(10)]retinyl acetate in a 0.5-g corn oil capsule and 300 g white maize porridge with 20 g butter
Number of subjects: 8
Study 21716163 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DRB1 alleles (specifically DR4, DR11, DR14)
Number of subjects: 141
Study 21716163 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligence and neuropsychological tests
Number of subjects: 141
Study 21716260 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 μg paricalcitol, orally active vitamin D receptor activator, every morning for 7 days
Number of subjects: 16
Study 21716303 — intervention group
Group type: EXPERIMENTAL
Intervention: NV1FGF
Number of subjects: 93
Study 21716303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 21717386 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (5 or 10 mg) daily for 12 months
Number of subjects: 11
Study 21719129 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP levels ≥2mg/L
Number of subjects: 142
Study 21719129 — intervention group
Group type: COMPARATOR
Intervention: hsCRP levels <2mg/L
Number of subjects: 142
Study 21719129 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher hsCRP levels
Number of subjects: 142
Study 21719129 — intervention group
Group type: COMPARATOR
Intervention: Lower hsCRP levels
Number of subjects: 142
Study 21719129 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP, LDL-cholesterol, BMI, and insulin resistance
Number of subjects: 142
Study 21719124 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Activity Profile (HAP)
Number of subjects: 101
Study 21719124 — intervention group
Group type: COMPARATOR
Intervention: SF-36v2™ Physical Component Summary (PCS)
Number of subjects: 101
Study 21719418 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR70 responders
Number of subjects: 205
Study 21719418 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS-28 remission
Number of subjects: 205
Study 21719418 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate improvements
Number of subjects: 205
Study 21719601 — intervention group
Group type: EXPERIMENTAL
Intervention: rVV-PR3
Number of subjects: 0
Study 21719601 — intervention group
Group type: EXPERIMENTAL
Intervention: PR2-specific splenocytes
Number of subjects: 0
Study 21719601 — intervention group
Group type: EXPERIMENTAL
Intervention: PR1-specific splenocytes
Number of subjects: 0
Study 21719746 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity, gastroesophageal reflux, and smoking (combined risk factors)
Number of subjects: 364
Study 21719746 — intervention group
Group type: EXPERIMENTAL
Intervention: High body mass index (≥30)
Number of subjects: 364
Study 21719746 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent acid reflux (≥1 time/week)
Number of subjects: 364
Study 21719746 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 364
Study 21719746 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent symptoms of acid reflux
Number of subjects: 364
Study 21719884 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide up to 30 mg daily for 16 weeks
Number of subjects: 28
Study 21721925 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment, twice a week for 6 weeks
Number of subjects: 24
Study 21723591 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin levels below 14 g/dL
Number of subjects: 64850
Study 21723591 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDS use
Number of subjects: 64850
Study 21723591 — intervention group
Group type: COMPARATOR
Intervention: Hemoglobin levels at or above 14 g/dL
Number of subjects: 64850
Study 21724047 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepafenac
Number of subjects: 0
Study 21725047 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative chemotherapy
Number of subjects: 0
Study 21725047 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy
Number of subjects: 0
Study 21725047 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 0
Study 21725050 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 5 mg daily for 56 days, then titrated up to 25 mg/d as tolerated
Number of subjects: 60
Study 21725050 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide therapy
Number of subjects: 60
Study 21725056 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipifarnib 300 mg twice daily on days 1-21 of each 28-day cycle
Number of subjects: 93
Study 21726125 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk subjects by FINRISK and SCORE models
Number of subjects: 120
Study 21726125 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk subjects by FINRISK at the extrapolated age of 60
Number of subjects: 120
Study 21726125 — intervention group
Group type: COMPARATOR
Intervention: Number of MetS variables
Number of subjects: 120
Study 21726849 — intervention group
Group type: EXPERIMENTAL
Intervention: DMEK with stromal gap or partial graft detachment
Number of subjects: 150
Study 21726849 — intervention group
Group type: EXPERIMENTAL
Intervention: DMEK with normal visual potential
Number of subjects: 150
Study 21726849 — intervention group
Group type: EXPERIMENTAL
Intervention: DMEK with upside-down graft
Number of subjects: 150
Study 21726849 — intervention group
Group type: EXPERIMENTAL
Intervention: Descemet graft implantation without endothelial graft
Number of subjects: 150
Study 21726862 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-adventitial diameter (IAD)
Number of subjects: 5641
Study 21726862 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular mass (LV mass)
Number of subjects: 5641
Study 21726862 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular mass (LV mass) for women
Number of subjects: 5641
Study 21726862 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular mass (LV mass) for men
Number of subjects: 5641
Study 21727108 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)
Number of subjects: 286
Study 21728727 — intervention group
Group type: EXPERIMENTAL
Intervention: Superion® Interspinous Spacer (Vertiflex, Inc., CA, USA)
Number of subjects: 0
Study 21729182 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled dust mite allergen challenge (Dermatophagoides farinae extract; PD(max) = fall in forced expiratory volume in 1 s of 10%)
Number of subjects: 12
Study 21729182 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled dust mite allergen challenge
Number of subjects: 12
Study 21729182 — intervention group
Group type: COMPARATOR
Intervention: No allergen challenge (baseline)
Number of subjects: 12
Study 21729732 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV-7 vaccine
Number of subjects: 89
Study 21730256 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized aggressive periodontitis (LAP)
Number of subjects: 53
Study 21730256 — intervention group
Group type: COMPARATOR
Intervention: Healthy sites
Number of subjects: 53
Study 21730256 — intervention group
Group type: EXPERIMENTAL
Intervention: LAP plasma
Number of subjects: 53
Study 21730273 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat CT scans performed within 15 minutes
Number of subjects: 0
Study 21731830 — intervention group
Group type: EXPERIMENTAL
Intervention: PHQ-9 suicide screening item
Number of subjects: 166
Study 21731830 — intervention group
Group type: COMPARATOR
Intervention: Structured Clinical Interview for DSM-IV (SCID-I mood module)
Number of subjects: 166
Study 21731831 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (2-15 mg/d; target of 5, 10, or 15 mg/d)
Number of subjects: 313
Study 21731831 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 313
Study 21731831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 21731833 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole
Number of subjects: 1092
Study 21731833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1092
Study 21731825 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (light smokers <20 cigarettes/day)
Number of subjects: 784
Study 21731825 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (heavy smokers ≥20 cigarettes/day)
Number of subjects: 784
Study 21731825 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 784
Study 21731825 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers (overall)
Number of subjects: 784
Study 21732212 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily self-weighing
Number of subjects: 1222
Study 21732212 — intervention group
Group type: COMPARATOR
Intervention: Monthly self-weighing
Number of subjects: 1222
Study 21732836 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler echocardiography
Number of subjects: 398
Study 21732836 — intervention group
Group type: EXPERIMENTAL
Intervention: Right heart catheterization
Number of subjects: 398
Study 21732836 — intervention group
Group type: COMPARATOR
Intervention: Echocardiography
Number of subjects: 398
Study 21732836 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed pulmonary hypertension
Number of subjects: 398
Study 21733227 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS-MPH treatment for 12 weeks
Number of subjects: 102
Study 21733476 — intervention group
Group type: EXPERIMENTAL
Intervention: Concise Health Risk Tracking scale - Clinician Rating (CHRT-C)
Number of subjects: 240
Study 21733476 — intervention group
Group type: EXPERIMENTAL
Intervention: Concise Health Risk Tracking scale - Self-Report (CHRT-SR)
Number of subjects: 240
Study 21733476 — intervention group
Group type: EXPERIMENTAL
Intervention: Concise Health Risk Tracking scale - both CHRT-C and CHRT-SR
Number of subjects: 240
Study 21733477 — intervention group
Group type: EXPERIMENTAL
Intervention: CAST Clinician Rating (CAST-C)
Number of subjects: 265
Study 21733477 — intervention group
Group type: EXPERIMENTAL
Intervention: CAST Self-Rated (CAST-SR)
Number of subjects: 265
Study 21733477 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-item CAST-C
Number of subjects: 265
Study 21733477 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-item CAST-SR
Number of subjects: 265
Study 21733483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive inhibition intervention
Number of subjects: 0
Study 21733483 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 21734313 — intervention group
Group type: EXPERIMENTAL
Intervention: RT3 accelerometers
Number of subjects: 0
Study 21734313 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 21735145 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib
Number of subjects: 0
Study 21735145 — intervention group
Group type: COMPARATOR
Intervention: axitinib
Number of subjects: 0
Study 21735145 — intervention group
Group type: COMPARATOR
Intervention: sorafenib-sunitinib
Number of subjects: 0
Study 21735145 — intervention group
Group type: COMPARATOR
Intervention: temsirolimus
Number of subjects: 0
Study 21735145 — intervention group
Group type: COMPARATOR
Intervention: sunitinib-everolimus
Number of subjects: 0
Study 21736514 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleus accumbens deep brain stimulation (NAcc-DBS)
Number of subjects: 10
Study 21737309 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg alteplase
Number of subjects: 103
Study 21737826 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of supervised treadmill and cycling exercise (60 min/day, 60-75% heart rate reserve)
Number of subjects: 11
Study 21738597 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-drug combination antiretroviral therapy (cART) including enfuvirtide for the first 6 months, optimized cART with three or more drugs for 12 months.
Number of subjects: 28
Study 21738752 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 21
Study 21738752 — intervention group
Group type: EXPERIMENTAL
Intervention: Allele-specific real-time PCR
Number of subjects: 21
Study 21740078 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan
Number of subjects: 0
Study 21740078 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study 21740082 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0
Study 21740082 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib in combination with arsenic trioxide, sorafenib, and cytarabine
Number of subjects: 0
Study 21740673 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric TB treatment given to 8 (40%) patients
Number of subjects: 20
Study 21740673 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline tuberculin skin tests ≥15 mm
Number of subjects: 20
Study 21740673 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte proliferative responses to Mycobacterium tuberculosis
Number of subjects: 20
Study 21740673 — intervention group
Group type: EXPERIMENTAL
Intervention: Fever ≥2 weeks plus ≥5 kg weight loss
Number of subjects: 20
Study 21740673 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal chest X-rays
Number of subjects: 20
Study 21740673 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive sputum cultures
Number of subjects: 20
Study 21740673 — intervention group
Group type: EXPERIMENTAL
Intervention: Median CD4 count
Number of subjects: 20
Study 21741058 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone treatment for 8 weeks
Number of subjects: 7
Study 21741076 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 231
Study 21742281 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) herbal concoctions taken orally for 24 weeks while continuing with Western medical management.
Number of subjects: 31
Study 21742281 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) herbal concoctions
Number of subjects: 31
Study 21743336 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonfils intubating fibrescope
Number of subjects: 41
Study 21744349 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-thermal-injury dissection device
Number of subjects: 20
Study 21744349 — intervention group
Group type: COMPARATOR
Intervention: Traditional electrosurgery
Number of subjects: 20
Study 21744485 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea therapy
Number of subjects: 0
Study 21744485 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea overdose (612 mg/kg body weight)
Number of subjects: 0
Study 21745716 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 0
Study 21745716 — intervention group
Group type: COMPARATOR
Intervention: Standard antimalarial therapy
Number of subjects: 0
Study 21746971 — intervention group
Group type: EXPERIMENTAL
Intervention: Descemet membrane endothelial keratoplasty
Number of subjects: 200
Study 21746992 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined patching and atropine
Number of subjects: 0
Study 21746992 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 21748299 — intervention group
Group type: EXPERIMENTAL
Intervention: Figitumumab 20 mg/kg in combination with carboplatin and paclitaxel
Number of subjects: 19
Study 21748299 — intervention group
Group type: EXPERIMENTAL
Intervention: Figitumumab (6, 10 and 20 mg/kg) in combination with carboplatin and paclitaxel
Number of subjects: 19
Study 21748299 — intervention group
Group type: EXPERIMENTAL
Intervention: Figitumumab
Number of subjects: 19
Study 21749463 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified epinephrine autoinjector trainer (red safety cap, yellow arrow)
Number of subjects: 164
Study 21749463 — intervention group
Group type: COMPARATOR
Intervention: Unmodified epinephrine autoinjector trainer
Number of subjects: 164
Study 21749641 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive ELISPOT assay
Number of subjects: 312
Study 21749641 — intervention group
Group type: COMPARATOR
Intervention: Negative or indeterminate ELISPOT assay
Number of subjects: 312
Study 21749641 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) treatment
Number of subjects: 312
Study 21749698 — intervention group
Group type: EXPERIMENTAL
Intervention: Single shot partial breast irradiation (SSPBI)
Number of subjects: 57
Study 21749698 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphic variant wt XRCC1Arg194Trp
Number of subjects: 57
Study 21749698 — intervention group
Group type: EXPERIMENTAL
Intervention: mut/het XRCC3Thr241Met
Number of subjects: 57
Study 21749698 — intervention group
Group type: EXPERIMENTAL
Intervention: wt/het XRCC3A4541G-5'UTR
Number of subjects: 57
Study 21749698 — intervention group
Group type: EXPERIMENTAL
Intervention: mut/het XRCC1Arg194Trp
Number of subjects: 57
Study 21749698 — intervention group
Group type: EXPERIMENTAL
Intervention: wt GSTA1
Number of subjects: 57
Study 21749698 — intervention group
Group type: EXPERIMENTAL
Intervention: wt XRCC1Arg399Gln
Number of subjects: 57
Study 21749698 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean dose to whole breast
Number of subjects: 57
Study 21749698 — intervention group
Group type: EXPERIMENTAL
Intervention: mut/het XRCC1Arg194Trp or wt XRCC3Thr241Met
Number of subjects: 57
Study 21749698 — intervention group
Group type: EXPERIMENTAL
Intervention: mut/het XRCC1Arg194Trp or wt GSTA1
Number of subjects: 57
Study 21751289 — intervention group
Group type: EXPERIMENTAL
Intervention: MR elastography (MRE)
Number of subjects: 9
Study 21752238 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid ultrasound screening
Number of subjects: 117
Study 21752238 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid ultrasound screening in men
Number of subjects: 117
Study 21752239 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric disorders among school dropouts
Number of subjects: 0
Study 21752239 — intervention group
Group type: COMPARATOR
Intervention: Matched control group of regularly enrolled students
Number of subjects: 0
Study 21752239 — intervention group
Group type: EXPERIMENTAL
Intervention: Family variables and socioeconomic status
Number of subjects: 0
Study 21752435 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 25mg weekly IV until progression or intolerable toxicity
Number of subjects: 54
Study 21752435 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Number of subjects: 54
Study 21752743 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet, oral antidiabetes agents, and/or injectables (insulin and/or GLP-1 analogues)
Number of subjects: 5000
Study 21752947 — intervention group
Group type: EXPERIMENTAL
Intervention: Vero cell antirabies vaccine
Number of subjects: 195
Study 21752947 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose after 5 years
Number of subjects: 195
Study 21754996 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ART (LPV/r+AZT+3TC)
Number of subjects: 17
Study 21755013 — intervention group
Group type: EXPERIMENTAL
Intervention: High ISG-expressing neutrophils
Number of subjects: 95
Study 21755013 — intervention group
Group type: COMPARATOR
Intervention: Normal ISG-expressing neutrophils
Number of subjects: 95
Study 21756035 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m² days 1, 4, 8, 11, 45, 52), cyclophosphamide (50 mg/kg days 15-18), pegfilgrastim (day 20)
Number of subjects: 81
Study 21756320 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured meal replacements with low glycemic index products and moderately high protein content during breakfast, morning snack, and afternoon snack.
Number of subjects: 17
Study 21756320 — intervention group
Group type: COMPARATOR
Intervention: Free living period with habitual ad libitum dietary pattern.
Number of subjects: 17
Study 21757257 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Body Skin Examination (TBSE)
Number of subjects: 14381
Study 21757572 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with PAH
Number of subjects: 2969
Study 21757572 — intervention group
Group type: COMPARATOR
Intervention: Men with PAH
Number of subjects: 2969
Study 21757586 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral GA
Number of subjects: 193
Study 21757586 — intervention group
Group type: COMPARATOR
Intervention: Early/intermediate AMD
Number of subjects: 193
Study 21757586 — intervention group
Group type: COMPARATOR
Intervention: Exudative AMD
Number of subjects: 193
Study 21757630 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 0
Study 21757630 — intervention group
Group type: COMPARATOR
Intervention: Desmopressin
Number of subjects: 0
Study 21757643 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic hypertension
Number of subjects: 50
Study 21757643 — intervention group
Group type: COMPARATOR
Intervention: Control (no intradialytic hypertension)
Number of subjects: 50
Study 21760564 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen treatment
Number of subjects: 252
Study 21760564 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography criteria
Number of subjects: 252
Study 21760886 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated-interferon/ribavirin
Number of subjects: 646
Study 21761342 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone supplementation in castrate mice
Number of subjects: 0
Study 21761342 — intervention group
Group type: COMPARATOR
Intervention: Low serum testosterone
Number of subjects: 0
Study 21761342 — intervention group
Group type: COMPARATOR
Intervention: Testosterone suppression
Number of subjects: 0
Study 21762873 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (10 mg, administered orally 30 min before HUT)
Number of subjects: 7
Study 21762873 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NAME (1 mg/kg, infused over a 60-min period)
Number of subjects: 7
Study 21762873 — intervention group
Group type: COMPARATOR
Intervention: No drug
Number of subjects: 7
Study 21763168 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically supervised fasts in children with the c.1436C→T variant
Number of subjects: 5